AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03500796 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound closure with amniotic membrane
Description: Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
Study NCT03785041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
Study NCT01979302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression CAREPATH
Description: Nurses receive training and agency support in depression assessment and depression care management
Study NCT01979302 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Nurses receive training in depression assessment and review of usual care procedures.
Study NCT02542722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
Study NCT02542722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Intervention
Description: Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
Study NCT00934622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® ReSTOR® Aspheric IOL
Description: AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
Study NCT04231994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPE
Description: singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin powder injection
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin powder injection
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine tablet
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine tablet
Study NCT03607656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM
Description: TCM decoction orally taken twice a day for at least 3 months
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 capsule
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 capsule
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel injection
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel injection
Study NCT06576336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic adrenalectomy
Description: laparoscopic adrenalectomy
Study NCT06576336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic adrenalectomy
Description: laparoscopic adrenalectomy
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU injection
Study NCT03607656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU injection
Study NCT02838329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warming of ropivacaine for BT
Study NCT02838329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Study NCT02838329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine
Study NCT03022929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Antimicrobial Stewardship Commitment and Feedback
Description: Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
Study NCT00883259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg twice daily
Study NCT00883259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcristallyne cellulose 1 table twice daily
Study NCT02713698 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL.
Study NCT00730392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
Study NCT00730392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
Study NCT03111849 — intervention group
Intervention type: OTHER
Intervention: sarcopenia
Description: Prevalence of sarcopenia in hospitalized chronic obstructive patients
Study NCT02758951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative systemic therapy
Description: Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
Study NCT02758951 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Perioperative CAPOX-bevacizumab
Description: Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
Study NCT02758951 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX-bevacizumab
Description: Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
Study NCT02758951 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFIRI-bevacizumab
Description: Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area \[BSA\] of irinotecan, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
Study NCT02758951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS-HIPEC, experimental arm
Description: CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy in case of sufficient clinical condition, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
Study NCT02758951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRS-HIPEC, control arm
Description: CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after randomisation.
Study NCT01778452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: endometrial biopsy
Study NCT01778452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial biopsy
Description: endometrial biopsy
Study NCT00883740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
Study NCT00883740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
Study NCT05399186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early preoperative assessment and optimization
Description: The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
Study NCT03284424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01426828 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CD3/CD28
Description: CD3/CD28 activated autologous lymphocytes intravenously
Study NCT03001869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HBED-CC-PSMA PET/CT
Description: 68Ga-HBED-CC-PSMA PET/CT Scan
Study NCT00729703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio DR 6550
Description: Dual-chamber ICD therapy with minimized ventricular pacing
Study NCT00729703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OVATIO DR 6550
Description: Single-chamber device therapy with settings which are common in clinical practice.
Study NCT02357173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic cigarette
Study NCT01253629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
Study NCT01253629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication identical in appearance to active medication was provided
Study NCT01622647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Description: Subjects will receive NCPAP
Study NCT02279875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Study NCT02376426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
Study NCT02376426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
Study NCT02279875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)
Description: isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
Study NCT04499144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified buccal flap and subepithelial connective palatal flap
Description: The connective flap was harvested from the deeper area of the palatal mucosa. Pedicle flap dimensions were reported using the periodontal probe. The flap was then rotated to cover the oro antral communication (OAC) area. The rotation could be in mesial or distal direction, related to OAC position and for the convenience of the donor site. The connective palatal flap was sutured to the buccal periostium using mattress sutures.
Study NCT04521062 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dilapan S
Description: Placement of Dilapan S
Study NCT03877068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM - Continues Glucose Monitoring sensor system
Description: A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.
Study NCT03877068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC BG - Point-of-Care Blood Glucose monitoring
Description: Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
Study NCT03877068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC BG - Point-of-Care Blood Glucose monitoring
Description: Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
Study NCT04398004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Treatment with 500 mg Clarithromycin orally twice daily for seven days
Study NCT03098719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Mobility
Description: see detailed discription
Study NCT02162537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
Study NCT02162537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: 500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
Study NCT02162537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
Study NCT02162537 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cerebral Radiotherapy
Description: Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
Study NCT02835547 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Study NCT02376426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
Study NCT02471924 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trans thoraciq cardiac ultrasonography
Description: Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
Study NCT00614029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sumatriptan (via Intraject System)
Description: 0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
Study NCT02357173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cigarette group
Study NCT00685048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 minutes of psycho-education
Description: Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
Study NCT00685048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 minutes of brief advice
Description: Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
Study NCT00685048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: four 50-minute individual therapy sessions of MET & CBT
Description: MET \& CBT
Study NCT04465916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets
Study NCT04465916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT04465916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Description: Oral tablets
Study NCT04465916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Description: Oral tablets
Study NCT01249690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib,Pirarubicin,Dexamethasone
Description: Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
Study NCT01249690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide,Pirarubicin,Dexamethasone
Description: Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
Study NCT02228369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3759
Description: Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
Study NCT02228369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 160mg once daily
Study NCT00155259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel , Cisplatin , Capecitabine
Study NCT00712907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C (Mayrhofer) 24mg/min i.v. for 64 min
Description: Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
Study NCT00712907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
Study NCT00712907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 100% O2 (AGA) two times for 12 min
Description: Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997
Study NCT00712907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 100% O2 (AGA) two times for 12 min
Description: Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997
Study NCT01106118 — intervention group
Intervention type: DRUG
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician